Target Name: RTL3
NCBI ID: G203430
Review Report on RTL3 Target / Biomarker Content of Review Report on RTL3 Target / Biomarker
RTL3
Other Name(s): ZCCHC5 | RTL3_HUMAN | Mar3 | retrotransposon Gag like 3 | Retrotransposon Gag-like protein 3 | ZHC5 | zinc finger CCHC domain-containing protein 5 | Mart3 | Sushi-Ichi retrotransposon homolog 9 | Retrotransposon Gag like 3 | zinc finger CCHC-type containing 5 | SIRH9 | mammalian retrotransposon-derived 3 | Mammalian retrotransposon-derived 3 | zinc finger, CCHC domain containing 5

Understanding The Role of RTL3 in Eye Health and Disease

RTL3 (short for retinal-derived layer 3) is a protein that is expressed in the retina of the eye. It is a transmembrane protein that is involved in the development and maintenance of the retina, and is thought to play a key role in the regulation of vision.

Recent studies have suggested that RTL3 may be a drug target (or biomarker) for the treatment of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because RTL3 has been shown to be involved in the development and progression of these diseases, and may be a useful target for therapeutic intervention.

One potential mechanism by which RTL3 may be involved in the development of cancer is by regulating the activity of immune cells that are involved in the immune response. Studies have shown that RTL3 can interact with immune cells and influence their function, potentially contributing to the development of cancer.

In addition, RTL3 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and are thought to be caused by the build-up of waste products in the brain.

RTL3 may be involved in the development and progression of these conditions because it is known to be involved in the production of these waste products. Studies have shown that RTL3 can interact with the neurotransmitter dopamine and contribute to the production of waste products that are thought to contribute to the progressive loss of brain cells in neurodegenerative diseases.

Finally, RTL3 may also be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, and are often treated with immunosuppressive drugs.

RTL3 may be involved in the development and progression of autoimmune disorders because it is known to be involved in the production of immune cells that contribute to the immune response. Studies have shown that RTL3 can interact with immune cells and influence their function, potentially contributing to the development and progression of autoimmune disorders.

In conclusion, RTL3 is a protein that is expressed in the retina and is involved in the development and maintenance of the retina. Recent studies have suggested that RTL3 may be a drug target (or biomarker) for the treatment of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because RTL3 has been shown to be involved in the development and progression of these diseases, and may be a useful target for therapeutic intervention. Further research is needed to fully understand the role of RTL3 in these conditions and to develop effective treatments.

Protein Name: Retrotransposon Gag Like 3

Functions: May function as a transcriptional regulator. Plays a role in postnatal myogenesis, may be involved in the regulation of satellite cells self-renewal

The "RTL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RTL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RTL4 | RTL5 | RTL6 | RTL8A | RTL8B | RTL8C | RTL9 | RTN1 | RTN2 | RTN3 | RTN4 | RTN4IP1 | RTN4R | RTN4RL1 | RTN4RL2 | RTP1 | RTP2 | RTP3 | RTP4 | RTP5 | RTRAF | RTTN | RUBCN | RUBCNL | RUFY1 | RUFY2 | RUFY3 | RUFY4 | RUNDC1 | RUNDC3A | RUNDC3A-AS1 | RUNDC3B | RUNX1 | RUNX1-IT1 | RUNX1T1 | RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2